查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1873982

过敏免疫疗法市场

Allergy Immunotherapies Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

2024年，过敏免疫疗法市值约为27.9亿美元，预计到2031年将成长至51.1亿美元，2031年之前的年复合成长率（CAGR）为9.0%。预计将影响过敏免疫疗法市场的关键趋势包括创新给药方法的开发、联合疗法的兴起以及个人化医疗的进步。

过敏免疫疗法市场分析

全球过敏性疾病发生率的不断上升有望推动过敏免疫疗法市场的成长。过敏性疾病数量的增加迫切需要有效的治疗方法，例如过敏免疫疗法。过敏免疫疗法被公认为一种安全有效的治疗方法，可用于控制昆虫霉菌、花粉、动物皮屑等过敏原以及过敏性气喘。根据美国过敏、气喘和免疫学会统计，2021年，美国有三分之一的成年人和超过四分之一的儿童报告患有季节性过敏、湿疹或食物过敏。

全球范围内过敏症的日益普遍推动了对免疫疗法的需求，从而促进了市场扩张。

过敏免疫疗法市场概览

全球过敏免疫疗法市场按地区划分为北美、欧洲、亚太、中东和非洲以及南美和中美洲。预计该市场将因过敏性疾病盛行率上升和舌下给药製剂技术进步等因素而成长。然而，过敏免疫疗法应用方面的挑战以及各地区监管差异可能会在预测期内阻碍市场成长。

战略洞察

过敏免疫疗法市场的驱动因素与机会

人们对过敏治疗的认识提高预计将有利于市场发展。

大众对过敏及其治疗方案的认识不断提高，推动了对更有效疗法的需求。人们希望缓解那些严重影响生活品质的症状。

州教育总监办公室 (OSSE) 和卫生与保健部门将 2023 年 5 月 14 日至 20 日定为食物过敏意识週，重点是向公众普及食物过敏和过敏性休克的相关知识。

强大的产品线为过敏免疫疗法市场带来了机会

目前，过敏性免疫疗法研发管线包含 15 种处于不同临床开发阶段的疗法。参与过敏性疾病免疫疗法研发的主要企业包括 Aimmune Therapeutics Inc.、DBV Technologies SA、Genentech Inc.、ASIT biotech SA、Inmunotek SL、Anergis SA、Biomay AG 和 Regeneron Pharmaceuticals Inc.。

临床试验中多种免疫疗法的积极临床结果支持了过敏免疫疗法药物的研发进展。例如，2022年11月，FDA授予Alladapt Immunotherapeutics公司的ADP101快速通道资格，ADP101是一种针对重要食物过敏原的在研口服免疫疗法。

对过敏免疫疗法市场进行分析的关键细分市场包括服务和应用。

  • 按治疗类型划分，过敏免疫疗法市场分为皮下免疫疗法 (SCIT) 和舌下免疫疗法 (SLIT)。 2023 年，SCIT 占据最大的市场份额，而预计在预测期内，SLIT 市场将实现最快的成长。
  • 依过敏类型划分，市场可分为过敏性鼻炎、气喘、食物过敏、毒液过敏和其他过敏。 2023年，过敏性鼻炎市占率最大，预计在预测期内将维持最高的复合年增长率。
  • 过敏免疫疗法市场按配销通路可细分为医院药房、零售药房和线上药房。 2023年，医院药局管道占据最大的市场份额，预计在预测期内也将保持最快的成长速度。

过敏免疫疗法的地理市场份额分析

过敏免疫疗法市场报告的地理范围分为五个地区：北美、亚太地区、欧洲、中东和非洲以及南美/中南美洲。

北美地区（包括美国、加拿大和墨西哥）占据过敏免疫疗法市场最大的份额，其中美国市场份额领先，加拿大紧随其后。美国市场份额显着增长主要归因于过敏性疾病盛行率的不断上升，这推动了对过敏免疫疗法的需求，进而促进了市场成长。此外，许多专注于过敏免疫疗法的製造商也促进了美国市场的扩张。同时，消费者对过敏治疗的认知不断提高，也增加了北美地区对医用氧气的需求。

亚太地区预计将成为所有区域中成长最快的地区。由于澳洲和印度等国家过敏和免疫性疾病的高发，亚太市场预计将快速成长。此外，各国政府旨在预防和治疗疾病的措施预计将为该地区创造有利的市场成长环境。同时，医疗基础设施的改善和研发投入的增加预计也将推动亚太地区过敏免疫疗法市场在预测期内的成长。

过敏免疫疗法市场报告范围

过敏免疫疗法市场最新动态及新闻

过敏免疫疗法市场评估是基于从一手和二手研究中收集的定性和定量资料，包括重要的企业出版物、协会资料和资料库。以下是过敏免疫疗法市场的一些最新发展和策略：

  • 2020年8月，雀巢健康科学收购了Aimmune Therapeutics公司。 Aimmune公司已获批准的疗法Palforzia是第一个也是目前唯一一个获得FDA批准的、用于降低儿童花生过敏反应频率和严重程度的药物，这将丰富雀巢健康科学的产品组合。 （来源：公司新闻稿）
  • 2023年9月，Stallergenes Greer与雀巢健康科学公司达成协议，使用花生过敏口服免疫疗法药物Palforzia。 （来源：公司新闻稿）

过敏免疫疗法市场报告的覆盖范围和交付成果

这份题为《过敏免疫疗法市场规模及预测（2021-2031）》的报告对市场进行了全面分析，涵盖以下领域：

  • 涵盖范围内所有关键细分市场的全球、区域和国家层面的市场规模和预测
  • 市场动态，例如驱动因素、限制因素和关键机会
  • 未来主要趋势
  • 详细的PEST/波特五力模型与SWOT分析
  • 全球及区域市场分析，涵盖关键市场趋势、主要参与者、法规及近期市场发展动态。
  • 产业格局和竞争分析，包括市场集中度、热力图分析、主要参与者和最新发展动态
  • 公司详细概况

目录

第一章：引言

第二章：过敏免疫疗法市场及主要结论

第三章：研究方法

  • 覆盖范围
  • 二手研究
  • 初步研究

第四章：过敏免疫疗法市场及市场概况

  • 概述
  • PEST分析
    • 北美和PEST分析
    • 欧洲和PEST分析
    • 亚太地区及PEST分析
    • 中东和非洲 (MEA) 及 PEST 分析
    • 南美洲和中美洲以及 PEST 分析
  • 专家意见

第五章：过敏免疫疗法市场及主要市场动态

  • 主要市场驱动因素
    • 过敏性疾病盛行率不断上升
    • 舌下给药製剂的技术进步
  • 关键市场限制因素
    • 使用过敏免疫疗法的缺点
    • 不同地区监理差异
  • 主要市场机会
    • 强大的产品线
  • 未来趋势
    • 增加FDA对药物的批准
  • 影响分析

第六章：过敏免疫疗法市场及全球分析

  • 全球过敏免疫疗法市场收入预测与分析
  • 全球过敏免疫疗法市场（按地域划分）－预测与分析
  • 关键参与者的市场定位

第七章：过敏免疫疗法市场分析及治疗方法

  • 概述
  • 按治疗方法分類的过敏免疫疗法市场份额，2024 年和 2031 年（%）
  • 皮下免疫疗法（SCIT）
  • 舌下免疫疗法（SLIT）

第八章：过敏免疫疗法市场分析及依过敏类型划分

  • 概述
  • 按过敏类型分類的过敏免疫疗法市场份额，2024 年和 2031 年（%）
  • 过敏性鼻炎
  • 气喘
  • 食物过敏
  • 毒液过敏
  • 其他过敏

第九章：过敏免疫疗法市场分析及配销通路

  • 概述
  • 按配销通路分類的过敏免疫疗法市场份额，2024 年和 2031 年（%）
  • 医院药房
  • 零售药房
  • 网路药房

第十章：过敏免疫疗法市场分析及至2031年预测及地理分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿联酋
    • 南非
  • 南美洲和中美洲
    • 巴西
    • 阿根廷

第十一章：新冠肺炎疫情对全球过敏免疫疗法市场的影响

  • 北美洲
  • 欧洲
  • 亚太地区
  • 世界其他地区

第十二章：过敏免疫疗法市场及产业概况

  • 概述
  • 市场中各公司采取的成长策略（%）
  • 有机发展
    • 概述
  • 无机物发展
    • 概述

第十三章：公司简介

  • ALK-Abello A/S
  • AIMMUNE THERAPEUTICS, INC.
  • LETIPharma
  • Stallergenes Greer
  • HAL Allergy B.V.
  • Johnson and Johnson Services, Inc.
  • Anergis
  • DBV Technologies
  • Dermapharm Holding
  • Allergy Therapeutics

第十四章：附录

简介目录
Product Code: TIPRE00008219

The allergy immunotherapies market was valued at approximately US$ 2.79 billion in 2024 and is anticipated to grow to US$ 5.11 billion by 2031, with a compound annual growth rate (CAGR) of 9.0% through 2031. Key trends expected to shape the allergy immunotherapies market include the development of innovative delivery methods, the rise of combination therapies, and advancements in personalized medicine.

Analysis of the Allergy Immunotherapies Market

The increasing incidence of allergic disorders globally is likely to propel the growth of the allergy immunotherapies market. The rising number of allergic conditions necessitates effective treatments such as allergy immunotherapy, which is recognized as a safe and effective approach to managing allergens like insect molds, pollen, and animal dander, as well as allergic asthma. According to the American College of Allergy, Asthma & Immunology, in 2021, one in three adults and over one in four children in the United States reported experiencing seasonal allergies, eczema, or food allergies.

The escalating prevalence of allergies worldwide is driving the demand for immunotherapies, thereby supporting market expansion.

Overview of the Allergy Immunotherapies Market

The global allergy immunotherapies market is categorized by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. Growth in this market is anticipated due to factors such as the rising prevalence of allergic disorders and technological advancements in sublingual dosage forms. However, challenges related to the use of allergy immunotherapies and regulatory differences across regions may hinder market growth during the forecast period.

Strategic Insights

Drivers and Opportunities in the Allergy Immunotherapies Market

Increased Awareness of Allergy Treatments is Expected to Benefit the Market

Growing public awareness regarding allergies and their treatment options is driving the demand for improved therapies. Individuals are seeking relief from symptoms that can significantly affect their quality of life.

The Office of the State Superintendent of Education (OSSE) and the Division of Health & Wellness recognized Food Allergy Awareness Week from May 14 to May 20, 2023, focusing on educating the public about food allergies and anaphylaxis.

Strong Product Pipeline Represents an Opportunity in the Allergy Immunotherapies Market

The pipeline for allergy immunotherapy includes 15 therapies at various clinical development stages. Key players involved in developing immunotherapies for allergic conditions include Aimmune Therapeutics Inc., DBV Technologies S.A., Genentech Inc., ASIT biotech SA, Inmunotek SL, Anergis S.A., Biomay AG, and Regeneron Pharmaceuticals Inc.

Positive clinical outcomes from various immunotherapies in clinical trials support the advancement of allergy immunotherapy drugs. For example, in November 2022, the FDA granted Fast Track designation to Alladapt Immunotherapeutics' ADP101, an investigational oral immunotherapy targeting significant food allergens.

Key segments contributing to the analysis of the allergy immunotherapies market include services and applications.

  • By treatment type, the allergy immunotherapies market is divided into subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). In 2023, the SCIT segment accounted for the largest market share, while the SLIT segment is projected to experience the fastest growth during the forecast period.
  • By allergy type, the market is segmented into allergic rhinitis, asthma, food allergies, venom allergies, and others. The allergic rhinitis segment held the largest market share in 2023 and is expected to register the highest CAGR during the forecast period.
  • The allergy immunotherapies market is also segmented by distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies. In 2023, the hospital pharmacy segment held the largest market share and is anticipated to grow the fastest during the forecast period.

Geographical Market Share Analysis of Allergy Immunotherapies

The geographical scope of the allergy immunotherapies market report is divided into five regions: North America, Asia Pacific, Europe, the Middle East & Africa, and South America/South & Central America.

North America, which includes the US, Canada, and Mexico, holds the largest share of the allergy immunotherapies market, with the US leading in market share, followed by Canada. The significant market share in the US is attributed to the increasing prevalence of allergic disorders, which boosts the demand for allergy immunotherapy and drives market growth. Additionally, the presence of numerous manufacturers specializing in allergy immunotherapy contributes to market expansion in the country. Furthermore, rising consumer awareness regarding allergy treatments has increased the demand for health supplemental oxygen in North America.

The Asia Pacific region is expected to be the fastest-growing area among all regions. The market in Asia Pacific is projected to grow rapidly due to the high prevalence of allergic and immunological diseases in countries like Australia and India. Moreover, government initiatives aimed at prevention and treatment strategies are expected to create a favorable market growth environment in the region. Additionally, improvements in healthcare infrastructure and increased investments in research activities are anticipated to drive the growth of the Asia Pacific Allergy Immunotherapies Market during the forecast period.

Scope of the Allergy Immunotherapies Market Report

Recent Developments and News in the Allergy Immunotherapies Market

The allergy immunotherapies market is assessed through qualitative and quantitative data collected from primary and secondary research, including significant corporate publications, association data, and databases. Below are some recent developments and strategies in the allergy immunotherapies market:

  • In August 2020, Nestle Health Science acquired Aimmune Therapeutics. Aimmune's approved therapy, Palforzia, would enhance Nestle Health Science's portfolio as the first and only FDA-approved treatment to reduce the frequency and severity of allergic reactions to peanuts in children. (Source: Company Press Release)
  • In September 2023, Stallergenes Greer entered into an agreement with Nestle Health Science to utilize the peanut allergy oral immunotherapy treatment, Palforzia. (Source: Company Press Release)

Coverage and Deliverables of the Allergy Immunotherapies Market Report

The report titled "Allergy Immunotherapies Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas:

  • Market size and forecast at global, regional, and country levels for all key market segments included in the scope
  • Market dynamics such as drivers, restraints, and key opportunities
  • Key future trends
  • Detailed PEST/Porter's Five Forces and SWOT analysis
  • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
  • Industry landscape and competition analysis, including market concentration, heat map analysis, prominent players, and recent developments
  • Detailed company profiles

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Allergy Immunotherapies Market and By Treatment
    • 1.3.2 Allergy Immunotherapies Market and By Allergy Type
    • 1.3.3 Allergy Immunotherapies Market and By Distribution Channel
    • 1.3.4 Allergy Immunotherapies Market and By Geography

2. Allergy Immunotherapies Market and Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Allergy Immunotherapies Market and Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America and PEST Analysis
    • 4.2.2 Europe and PEST Analysis
    • 4.2.3 Asia-Pacific and PEST Analysis
    • 4.2.4 Middle East and Africa (MEA) and PEST Analysis
    • 4.2.5 South and Central America and PEST Analysis
  • 4.3 Expert Opinion

5. Allergy immunotherapies Market and Key Market Dynamics

  • 5.1 Key Market Drivers
    • 5.1.1 Growing Prevalence of Allergic Disorders
    • 5.1.2 Technological Advancements in Sublingual Dosage Formulations
  • 5.2 Key Market Restraint
    • 5.2.1 Drawbacks Associated with the Use of Allergy Immunotherapy
    • 5.2.2 Regulatory Variations Across Regions
  • 5.3 Key Market Opportunities
    • 5.3.1 Presence of Strong Product Pipeline
  • 5.4 Future Trends
    • 5.4.1 Increasing FDA Approvals for Drugs
  • 5.5 Impact Analysis

6. Allergy Immunotherapies Market and Global Analysis

  • 6.1 Global Allergy Immunotherapies Market Revenue Forecast And Analysis
  • 6.2 Global Allergy immunotherapies market, By Geography - Forecast And Analysis
  • 6.3 Market Positioning of Key Players

7. Allergy Immunotherapies Market Analysisand by Treatment

  • 7.1 Overview
  • 7.2 Allergy Immunotherapies Market Share, By Treatment, 2024 and 2031 (%)
  • 7.3 Subcutaneous Immunotherapy (SCIT)
    • 7.3.1 Overview
    • 7.3.2 Subcutaneous Immunotherapy (SCIT) Market Revenue and Forecasts to 2031 (US$ Million)
  • 7.4 Sublingual Immunotherapy (SLIT)
    • 7.4.1 Overview
    • 7.4.2 Sublingual Immunotherapy (SLIT) Market Revenue and Forecasts to 2031 (US$ Million)

8. Allergy Immunotherapies Market Analysisand by Allergy Type

  • 8.1 Overview
  • 8.2 Allergy Immunotherapies Market Share, By Allergy Type, 2024 and 2031 (%)
  • 8.3 Allergic Rhinitis
    • 8.3.1 Overview
    • 8.3.2 Allergic Rhinitis Market Revenue and Forecasts to 2031 (US$ Million)
  • 8.4 Asthma
    • 8.4.1 Overview
    • 8.4.2 Asthma Market Revenue and Forecasts to 2031 (US$ Million)
  • 8.5 Food Allergy
    • 8.5.1 Overview
    • 8.5.2 Food Allergy Market Revenue and Forecasts to 2031 (US$ Million)
  • 8.6 Venom Allergy
    • 8.6.1 Overview
    • 8.6.2 Venom Allergy Market Revenue and Forecasts to 2031 (US$ Million)
  • 8.7 Other Allergies
    • 8.7.1 Overview
    • 8.7.2 Others Market Revenue and Forecasts to 2031 (US$ Million)

9. Allergy Immunotherapies Market Analysisand by Distribution Channel

  • 9.1 Overview
  • 9.2 Allergy Immunotherapies Market Share, By Distribution Channel, 2024 and 2031 (%)
  • 9.3 Hospital Pharmacy
    • 9.3.1 Overview
    • 9.3.2 Hospital Pharmacy Market Revenue and Forecasts to 2031 (US$ Million)
  • 9.4 Retail Pharmacy
    • 9.4.1 Overview
    • 9.4.2 Retail Pharmacy Market Revenue and Forecasts to 2031 (US$ Million)
  • 9.5 Online Pharmacy
    • 9.5.1 Overview
    • 9.5.2 Online Pharmacy Market Revenue and Forecasts to 2031 (US$ Million)

10. Allergy Immunotherapies Market Analysis And Forecasts To 2031 and Geographical Analysis

  • 10.1 North America: Allergy immunotherapies market
    • 10.1.1 Overview
    • 10.1.2 North America : Allergy immunotherapies market - Revenue and Forecast to 2031 (US$ Million)
    • 10.1.3 North America: Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
    • 10.1.4 North America Allergy immunotherapies market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
    • 10.1.5 North America Allergy immunotherapies market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.1.6 North America: Allergy immunotherapies market, by Country, 2024 and 2031 (%)
    • 10.1.7 US: Allergy immunotherapies market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.1 US: Allergy immunotherapies market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.2 US Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.3 US Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.4 US Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.1.8 Canada: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.1 Canada: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.2 Canada Allergy immunotherapies market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.3 Canada Allergy immunotherapies market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.4 Canada Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.1.9 Mexico: Allergy immunotherapies market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.1 Mexico: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.2 Mexico Allergy immunotherapies market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.3 Mexico Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.4 Mexico Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
  • 10.1 Europe: Allergy Immunotherapies Market
    • 10.1.1 Overview
    • 10.1.2 Europe: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
    • 10.1.3 Europe: Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
    • 10.1.4 Europe: Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
    • 10.1.5 Europe: Allergy Immunotherapies Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.1.6 Europe: Allergy Immunotherapies Market, by Country, 2024 and 2031 (%)
    • 10.1.7 Germany: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.1 Germany: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.2 Germany: Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.3 Germany: Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.1.7.4 Germany: Allergy Immunotherapies Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.1.8 France: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.1 France: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.2 France: Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.3 France: Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.1.8.4 France: Allergy Immunotherapies Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.1.9 UK: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.1 UK: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.2 UK: Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.3 UK: Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.1.9.4 UK: Allergy Immunotherapies Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.1.10 Italy: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.10.1 Italy: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.10.2 Italy: Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.1.10.3 Italy: Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.1.10.4 Italy: Allergy Immunotherapies Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.1.11 Spain: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.11.1 Spain: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.1.11.2 Spain: Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.1.11.3 Spain: Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.1.11.4 Spain: Allergy Immunotherapies Market, Distribution Channel and Revenue and Forecast to 2031 (USD Million)
  • 10.2 Asia-Pacific: Allergy Immunotherapies Market
    • 10.2.1 Overview
    • 10.2.2 Asia-Pacific: Allergy Immunotherapies Market - Revenue and Forecast to 2031 (USD Million)
    • 10.2.3 Asia-Pacific Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
    • 10.2.4 Asia-Pacific Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
    • 10.2.5 Asia-Pacific Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.2.6 Asia-Pacific: Allergy Immunotherapies Market, by Country, 2024 and 2031 (%)
    • 10.2.7 China: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.7.1 China: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Millkion)
      • 10.2.7.2 China Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.2.7.3 China Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.2.7.4 China Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.2.8 Japan: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.8.1 Japan: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.8.2 Japan Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.2.8.3 Japan Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.2.8.4 Japan Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.2.9 India: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.9.1 India: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.9.2 India Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.2.9.3 India Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.2.9.4 India Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.2.10 South Korea: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.10.1 South Korea: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.10.2 South Korea Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.2.10.3 South Korea Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.2.10.4 South Korea Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.2.11 Australia: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.11.1 Australia: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.2.11.2 Australia Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.2.11.3 Australia Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.2.11.4 Australia Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
  • 10.3 Middle East and Africa: Allergy immunotherapies market
    • 10.3.1 Overview
    • 10.3.2 Middle East and Africa: Allergy immunotherapies market - Revenue and Forecast to 2031 (US$ Million)
    • 10.3.3 Middle East and Africa Allergy immunotherapies market, by Treatment and Revenue and Forecast to 2031 (USD Million)
    • 10.3.4 Middle East and Africa Allergy immunotherapies market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
    • 10.3.5 Middle East and Africa Allergy immunotherapies market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.3.6 Middle East and Africa: Allergy Immunotherapies Market, by Country, 2024 and 2031 (%)
    • 10.3.7 Saudi Arabia: Allergy immunotherapies market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.7.1 Saudi Arabia: Allergy immunotherapies market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.7.2 Saudi Arabia Allergy immunotherapies market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.3.7.3 Saudi Arabia Allergy immunotherapies market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.3.7.4 Saudi Arabia Allergy immunotherapies market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.3.8 UAE: Allergy immunotherapies market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.8.1 UAE: Allergy immunotherapies market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.8.2 UAE Allergy Immunotherapies Market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.3.8.3 UAE Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.3.8.4 UAE Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.3.9 South Africa: Allergy immunotherapies market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.9.1 South Africa: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.3.9.2 South Africa Allergy immunotherapies market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.3.9.3 South Africa Allergy immunotherapies market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.3.9.4 South Africa Allergy Immunotherapies Market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
  • 10.4 South and Central America: Allergy immunotherapies market
    • 10.4.1 Overview
    • 10.4.2 South and Central America: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
    • 10.4.3 South and Central America Allergy immunotherapies market, by Treatment and Revenue and Forecast to 2031 (USD Million)
    • 10.4.4 South and Central America Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
    • 10.4.5 South and Central America Allergy immunotherapies market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.4.6 South and Central America: Allergy immunotherapies Market, by Country, 2024 and 2031 (%)
    • 10.4.7 Brazil: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.4.7.1 Brazil: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.4.7.2 Brazil Allergy immunotherapies market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.4.7.3 Brazil Allergy immunotherapies market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.4.7.4 Brazil Allergy immunotherapies market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)
    • 10.4.8 Argentina: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.4.8.1 Argentina: Allergy Immunotherapies Market and Revenue and Forecast to 2031 (USD Million)
      • 10.4.8.2 Argentina Allergy immunotherapies market, by Treatment and Revenue and Forecast to 2031 (USD Million)
      • 10.4.8.3 Argentina Allergy Immunotherapies Market, by Allergy Type and Revenue and Forecast to 2031 (USD Million)
      • 10.4.8.4 Argentina Allergy immunotherapies market, by Distribution Channel and Revenue and Forecast to 2031 (USD Million)

11. Impact of COVID-19 Pandemic on Global Allergy Immunotherapies Market

  • 11.1 North America: Impact Assessment of COVID-19 Pandemic
  • 11.2 Europe: Impact Assessment of COVID-19 Pandemic
  • 11.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
  • 11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Allergy Immunotherapies Market and Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies Done by the Companies in the Market, (%)
  • 12.3 Organic Developments
    • 12.3.1 Overview
  • 12.4 Inorganic Developments
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 ALK-Abello A/S
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 AIMMUNE THERAPEUTICS, INC.
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 LETIPharma
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Stallergenes Greer
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 HAL Allergy B.V.
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Johnson and Johnson Services, Inc.
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Anergis
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 DBV Technologies
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Dermapharm Holding
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Allergy Therapeutics
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 Glossary of Terms